Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

European guidelines on managing adverse effects of medication for ADHD.

Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E; European Guidelines Group.

Eur Child Adolesc Psychiatry. 2011 Jan;20(1):17-37. doi: 10.1007/s00787-010-0140-6. Epub 2010 Nov 3.

2.

ADHD update: new data on the risks of medication.

[No authors listed]

Harv Ment Health Lett. 2006 Oct;23(4):3-5. No abstract available.

PMID:
17183739
3.

Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.

Santosh PJ, Sattar S, Canagaratnam M.

CNS Drugs. 2011 Sep 1;25(9):737-63. doi: 10.2165/11593070-000000000-00000. Review.

PMID:
21870887
4.

Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.

Fredriksen M, Dahl AA, Martinsen EW, Klungsøyr O, Haavik J, Peleikis DE.

Eur Neuropsychopharmacol. 2014 Dec;24(12):1873-84. doi: 10.1016/j.euroneuro.2014.09.013. Epub 2014 Oct 18.

PMID:
25453480
5.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
6.
7.

Acute suicidality after commencing atomoxetine.

Paxton GA, Cranswick NE.

J Paediatr Child Health. 2008 Oct;44(10):596-8. doi: 10.1111/j.1440-1754.2008.01389.x.

PMID:
19012633
8.

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E.

Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490.

9.

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.

Gibson AP, Bettinger TL, Patel NC, Crismon ML.

Ann Pharmacother. 2006 Jun;40(6):1134-42. Epub 2006 May 30. Review.

PMID:
16735655
10.

Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.

Hennessy S, Schelleman H, Daniel GW, Bilker WB, Kimmel SE, Guevara J, Cziraky MJ, Strom BL.

Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):934-41. doi: 10.1002/pds.1992.

PMID:
20623519
11.

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Eiland LS, Bell EA, Erramouspe J.

Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Review.

PMID:
24982313
12.
13.
14.

Close up on atomoxetine: a nonstimulant choice for treating ADHD.

Allen C, Pitcock J.

Adv Nurse Pract. 2006 Mar;14(3):39-40, 42-3, 78. Review. No abstract available.

PMID:
16548127
15.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
16.
17.

Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.

Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Graham J, Taylor E, Sergeant J; European ADHD Guidelines Group.

J Child Psychol Psychiatry. 2013 Mar;54(3):227-46. doi: 10.1111/jcpp.12036. Epub 2013 Jan 7. Review.

PMID:
23294014
18.

[My child is so restless].

Schlamp D.

MMW Fortschr Med. 2007 Mar 8;149(10):39-40. Review. German.

PMID:
17408047
19.

[Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications].

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E.

Z Kinder Jugendpsychiatr Psychother. 2008 Mar;36(2):97-106; quiz 106-7. doi: 10.1024/1422-4917.36.2.97. Review. German.

PMID:
18622939
20.

ADHD treatments, sleep, and sleep problems: complex associations.

Stein MA, Weiss M, Hlavaty L.

Neurotherapeutics. 2012 Jul;9(3):509-17. doi: 10.1007/s13311-012-0130-0. Review.

Supplemental Content

Support Center